Clinical Deep Dives

Medlock Holmes is called to investigate a troubling mystery among the youngest citizens of the city.

There is no dealer on the street corner.

No hidden laboratory.

No expensive supply chain.

Instead, the clues are ordinary household objects: glue, paint thinner, spray cans, lighter fluid, petrol, correction fluid, cleaning products, and aerosol dusters.

At first, the city dismisses the danger.

These are not “real drugs”, people say.

They are products.

They are everywhere.

But Holmes knows that availability can be the most dangerous disguise of all.

Inhalants are volatile substances that rapidly vaporise and are inhaled for psychoactive effects. Their intoxication arrives quickly because the lungs deliver these chemicals directly into the bloodstream and then to the brain. Within minutes, a young person may experience euphoria, disinhibition, dizziness, slurred speech, unsteady gait, hallucinations, confusion, or collapse.

Holmes notices that inhalant use is especially common in early adolescence. The appeal is obvious: the substances are cheap, legal, easy to conceal, and difficult to detect on routine toxicology screens. Yet the danger is profound. A single episode can cause suffocation, aspiration, burns, trauma, seizures, coma, respiratory depression, or sudden cardiac death.

As Holmes follows the trail deeper, he discovers that chronic inhalant use is not merely a behavioural problem. It is a toxic assault on the body. The brain, rich in lipids and myelinated tissue, is particularly vulnerable. Long-term use can damage white matter, impair memory and executive functioning, cause cerebellar problems, produce neuropathy, and contribute to major or mild neurocognitive disorder.

The investigation also reveals a familiar pattern of psychiatric complexity. Inhalant use is often associated with conduct disorder, trauma, neglect, suicidality, mood and anxiety disorders, antisocial traits, and polysubstance use. For some adolescents, experimentation stops quickly. For others, inhalants become an early warning signal of a much broader developmental pathway involving impulsivity, risk-taking, marginalisation, and future substance dependence.

Treatment is difficult because the evidence base is limited. There is no simple medication that reverses inhalant use disorder. Care requires careful medical assessment, management of intoxication, attention to neurological and cognitive injury, family work, trauma-informed care, school and social support, relapse prevention, and treatment of comorbid psychiatric and substance use disorders.

By the end of the case, Holmes realises that inhalants are dangerous precisely because they are ordinary.

The threat does not always arrive wearing the face of crime.

Sometimes it sits quietly on a shelf, waiting to be misunderstood.

Key Takeaways

* Inhalants are volatile substances inhaled for psychoactive effects.

* Common sources include glues, paints, thinners, fuels, aerosols, cleaning products, correction fluids, and dusters.

* Use is most common in younger adolescents and tends to decline with age.

* Inhalant intoxication can cause euphoria, disinhibition, dizziness, slurred speech, ataxia, hallucinations, confusion, stupor, coma, or death.

* A single episode may be fatal through arrhythmia, suffocation, aspiration, respiratory depression, burns, trauma, or seizures.

* Routine drug screens often miss inhalant use.

* Clues include chemical odour, stained clothing, solvent-soaked rags, bags, aerosol cans, or perioral/perinasal rash.

* Chronic use can cause neurological injury, white matter damage, cognitive impairment, neuropathy, cerebellar signs, and neurocognitive disorder.

* Inhalant use is strongly associated with conduct disorder, trauma, suicidality, polysubstance use, mood disorders, anxiety disorders, and social adversity.

* Inhalant-induced psychiatric disorders may include delirium, psychosis, depressive disorder, anxiety disorder, and neurocognitive disorder.

* Management of intoxication is mainly supportive, with careful monitoring of airway, breathing, circulation, consciousness, and cardiac risk.

* Agitation should be managed cautiously because physical excitement may increase arrhythmia risk.

* Benzodiazepines may worsen respiratory depression during acute intoxication and require caution.

* Treatment of inhalant use disorder usually requires broad biopsychosocial care rather than substance-specific medication.

* Prevention, early recognition, family involvement, and community support are especially important.

Medlock Holmes is called to investigate a series of extraordinary reports.

One witness describes colours that seem alive. Another believes time has stopped. A third feels completely detached from their own body, while another speaks of overwhelming love, profound spiritual insight, or terrifying paranoia. Some recover within hours, while others continue to experience disturbing visual phenomena months or even years later.

At first glance, every case appears to point towards severe mental illness.

Yet Holmes notices an important clue.

These experiences all follow exposure to substances capable of profoundly altering consciousness.

This chapter explores the fascinating and rapidly evolving world of hallucinogen-related disorders. Unlike many other psychoactive substances, hallucinogens primarily alter perception, awareness, emotion, and the sense of self while often leaving consciousness intact. Rather than simply causing intoxication, they reshape how reality itself is experienced.

Holmes discovers that “hallucinogen” is actually an umbrella term covering remarkably different substances. Classic psychedelics such as LSD, psilocybin, mescaline and DMT primarily act through serotonin receptors and produce vivid perceptual changes and altered states of consciousness. Dissociative agents such as ketamine and PCP disrupt the normal integration of sensory information, creating feelings of detachment from the body and environment. MDMA occupies another category altogether, enhancing emotional connectedness and empathy while also carrying significant medical risks. Other naturally occurring compounds, including salvinorin A and ibogaine, produce unique alterations of consciousness through entirely different neurochemical pathways.

As Holmes interviews each individual, he realises that the same substance can produce vastly different experiences depending on the person, their expectations, and the environment in which it is taken. The concepts of “set” and “setting” emerge as critical determinants of whether the experience becomes therapeutic, frightening, enlightening, or dangerous.

Most episodes resolve without lasting harm, but some do not.

Holmes encounters individuals overwhelmed by panic during intoxication, others developing prolonged psychotic symptoms, and some experiencing persistent visual disturbances long after the drug has left their body. Hallucinogen Persisting Perception Disorder (HPPD) reminds him that, for a small number of people, altered perception can continue long after the original experience has ended, creating significant distress despite intact insight.

The chapter also explores one of psychiatry’s most intriguing paradoxes.

For decades these substances were viewed almost exclusively as drugs of misuse. Today, carefully controlled clinical research is once again investigating psychedelic-assisted therapies for treatment-resistant depression, post-traumatic stress disorder, addiction, and end-of-life distress. Ketamine has already become an established treatment for resistant depression, while other compounds continue to be evaluated in rigorous clinical trials.

Holmes recognises that this changing landscape creates new responsibilities for clinicians. Patients may increasingly ask about psychedelic therapies, experiment with self-treatment, or present with complications of recreational use. Understanding both the potential benefits and the risks becomes essential.

By the conclusion of the investigation, Holmes reaches a balanced perspective.

Hallucinogens are neither miracle medicines nor simply dangerous drugs.

They are powerful tools capable of profoundly altering consciousness. Used in uncontrolled settings, they may produce medical emergencies, psychological trauma, or persistent psychiatric disorders. Used carefully within structured therapeutic environments, they may eventually transform aspects of psychiatric treatment.

The challenge for modern psychiatry is to approach these substances with curiosity, scientific rigour, and clinical caution-avoiding both fear and uncritical enthusiasm.

Key Takeaways

* Hallucinogens alter perception, consciousness, emotion, and sense of self without typically causing delirium.

* Major classes include classic psychedelics, dissociatives, entactogens, and several naturally occurring compounds.

* Different hallucinogens act through different neurochemical mechanisms.

* “Set” and “setting” strongly influence the psychological experience.

* Acute intoxication may present with anxiety, panic, perceptual distortions, paranoia, or psychosis.

* PCP and ketamine are more likely to produce severe behavioural disturbance and medical complications.

* Hallucinogen Persisting Perception Disorder (HPPD) causes recurrent perceptual disturbances after drug use.

* Hallucinogen-induced psychosis may occur, particularly in vulnerable individuals.

* Management focuses on supportive care, reassurance, benzodiazepines when required, and treatment of medical complications.

* Ketamine is now established in psychiatric treatment, while psilocybin and MDMA continue to be investigated for therapeutic use.

* Clinicians should distinguish substance-induced disorders from primary psychiatric illnesses.

* Understanding both the risks and therapeutic potential of psychedelics is becoming increasingly important for modern psychiatric practice.

Cannabis is often viewed as harmless, natural, or even medicinal, yet its relationship with mental health is far more complex. In this episode, Medlock Holmes investigates how THC alters brain function, why some people develop dependence while others do not, and the growing evidence linking cannabis with anxiety, psychosis, cognitive impairment, and withdrawal. As cannabis becomes increasingly potent and widely available, Holmes uncovers the delicate balance between therapeutic potential and psychiatric risk.

Key Takeaways

* Cannabis is the most widely used illicit drug worldwide.

* THC is the primary psychoactive cannabinoid and acts mainly through CB1 receptors in the brain.

* Modern cannabis products contain much higher THC concentrations than in previous decades.

* Cannabis can be smoked, vaped, ingested as edibles, or consumed as concentrated extracts.

* Acute intoxication commonly causes euphoria, relaxation, altered perception, impaired attention, poor short-term memory, and slowed reaction time.

* Motor coordination and driving ability are significantly impaired during intoxication.

* Regular cannabis use can lead to Cannabis Use Disorder, characterised by impaired control, craving, tolerance, withdrawal, and continued use despite harm.

* Approximately 1 in 10 people who ever use cannabis develop dependence, rising to around 1 in 3 among regular users.

* Withdrawal usually begins within 24–48 hours and includes irritability, anxiety, insomnia, reduced appetite, restlessness, depressed mood, sweating, tremor, headache, and abdominal discomfort.

* Heavy cannabis use is associated with poorer educational outcomes, reduced cognitive performance, and impaired memory, particularly with early adolescent use.

* High-potency cannabis increases the risk of psychotic symptoms and may precipitate schizophrenia in genetically vulnerable individuals.

* Continued cannabis use after a first episode of psychosis is associated with poorer clinical outcomes and higher relapse rates.

* Cannabis may also worsen anxiety, trigger panic attacks, and contribute to cannabinoid hyperemesis syndrome in chronic heavy users.

* Acute cannabis use increases heart rate and can pose cardiovascular risks in susceptible individuals.

* There is no approved pharmacological treatment for Cannabis Use Disorder.

* The most effective treatments combine motivational enhancement therapy (MET), cognitive behavioural therapy (CBT), relapse prevention, contingency management, and family-based interventions for adolescents.

* Medicinal cannabinoids have evidence for selected conditions including chemotherapy-induced nausea, multiple sclerosis spasticity, certain epilepsies, and some chronic pain conditions, but evidence remains limited for many psychiatric disorders.

Every morning, before the city truly awakens, Medlock Holmes notices a remarkable ritual.

Office lights flicker on.

Coffee machines begin to hiss.

Kettles whistle.

Students cradle steaming mugs.

Doctors begin ward rounds with takeaway cups in hand.

Parents finally feel awake after the first sip.

Unlike the illicit drugs Holmes has investigated before, no one hides this substance.

It is celebrated.

Shared.

Offered to guests.

Embedded within culture itself.

Yet Holmes is puzzled.

How can the world’s most socially accepted psychoactive substance also be capable of intoxication, withdrawal, anxiety, insomnia, dependence, and addiction?

His newest investigation begins not in a crime scene-but in a café.

Holmes quickly discovers that caffeine is the most widely consumed psychoactive drug in the world, with around 90% of adults consuming it regularly. It is naturally present in coffee, tea, cocoa, yerba mate and many other plants, while manufacturers also add it to soft drinks, energy drinks, medications, dietary supplements and foods.

Unlike amphetamines or cocaine, caffeine works primarily by blocking adenosine receptors.

Adenosine normally acts like the brain’s biological brake pedal.

Throughout the day, adenosine gradually accumulates.

The more adenosine binds to its receptors, the sleepier we become.

Caffeine disguises itself as adenosine.

It occupies the receptor without activating it.

The brake disappears.

The brain becomes more alert.

Indirectly, dopamine signalling also increases, producing greater motivation, attention and reward.

Holmes smiles.

“The engine,” he says, “was never made stronger.”

“You merely disconnected the brakes.”

The chapter explores the remarkable pharmacology of caffeine.

After ingestion, caffeine is rapidly absorbed, reaching peak blood levels within approximately 30–60 minutes. Its average half-life is four to six hours, although this varies considerably depending on genetics, pregnancy, oral contraceptive use, smoking, liver disease and interacting medications. Slow metabolisers may experience caffeine’s effects for far longer than expected.

Holmes begins interviewing patients.

Each tells a different story.

A medical student drinks two coffees before an examination and feels focused.

A lawyer drinks six coffees and cannot stop pacing.

A teenager consumes multiple energy drinks before sport and develops palpitations.

A psychiatrist cannot function until the second cup each morning.

The same molecule.

Different brains.

Different outcomes.

Holmes learns that caffeine’s effects are strongly dose dependent.

Low to moderate doses (around 20–200 mg) typically improve alertness, energy, concentration, mood and motivation while reducing fatigue.

At higher doses (usually ≥400 mg), benefits begin to disappear.

Instead, anxiety, nervousness, tremor, jitteriness and restlessness emerge. Performance may actually worsen despite feeling more awake.

He remarks:

“The dose decides whether caffeine becomes an ally-or an adversary.”

His next investigation concerns caffeine intoxication.

Unlike alcohol intoxication, most people never intend to become intoxicated with caffeine.

Instead, it happens accidentally.

Extra coffees during deadlines.

Multiple energy drinks during examinations.

Workout supplements combined with coffee.

Weight-loss tablets.

Cold medications.

The total quietly accumulates.

DSM-5-TR suggests intoxication generally follows recent consumption well above 250 mg, although more severe presentations often involve much larger doses. Typical symptoms include:

* Restlessness

* Nervousness

* Excitement

* Insomnia

* Diuresis

* Gastrointestinal upset

* Muscle twitching

* Rambling speech

* Tachycardia

* Psychomotor agitation

Severe overdose may produce vomiting, seizures, delirium, arrhythmias and, rarely, death. Fatal toxicity is uncommon and usually involves caffeine tablets or powder rather than beverages.

Holmes notices something interesting.

Patients rarely realise that their “panic attack” may actually be caffeine intoxication.

The next mystery surprises him even more.

Not intoxication.

Withdrawal.

One woman develops a terrible headache every Sunday morning.

Another develops “influenza” during religious fasting.

A surgeon repeatedly experiences postoperative headaches.

Each mystery has the same explanation.

No caffeine.

The chapter explains that regular caffeine use produces genuine physical dependence. Withdrawal typically begins 12–24 hours after cessation, peaks during the first 48 hours and usually resolves within two to nine days. The hallmark symptom is headache, but fatigue, drowsiness, depressed mood, poor concentration, irritability, nausea, muscle aches and flu-like symptoms are also common. Even relatively modest daily consumption (around 100 mg) may produce withdrawal in susceptible individuals.

Holmes reflects:

“People often mistake withdrawal for illness.”

“In reality, they are experiencing the absence of something they believed they never depended upon.”

Another patient arrives convinced she has developed an anxiety disorder.

Holmes notices something unusual.

She drinks eight large coffees every day.

Her anxiety worsens steadily throughout the afternoon.

Rather than prescribing anxiolytics immediately, Holmes performs a simple experiment.

He gradually reduces her caffeine intake.

The anxiety disappears.

The chapter describes caffeine-induced anxiety disorder, recognising that caffeine may precipitate panic attacks or clinically significant anxiety, particularly in susceptible individuals or those with existing anxiety disorders. A trial of caffeine reduction or abstinence is often diagnostically useful before escalating pharmacological treatment.

Sleep presents another paradox.

Many people drink coffee because they are tired.

Later, they cannot sleep because they drank coffee.

The following morning they require more coffee.

Holmes sketches a circle.

Fatigue.

Coffee.

Poor sleep.

More fatigue.

More coffee.

The chapter explains caffeine-induced sleep disorder, most commonly insomnia. Even 200 mg consumed before bedtime may delay sleep onset, reduce total sleep time and impair sleep quality, while caffeine taken earlier in the day may still affect sleep later that night in sensitive individuals. Although habitual users develop partial tolerance, the sleep-disrupting effects are never completely eliminated.

Holmes is initially reluctant to believe that caffeine can produce a genuine use disorder.

After all...

People joke about “coffee addiction.”

The chapter suggests the joke is sometimes true.

DSM-5-TR currently lists Caffeine Use Disorder as a condition for further study.

The proposed diagnosis requires three core features:

* Persistent unsuccessful attempts to reduce caffeine.

* Continued use despite physical or psychological harm.

* Withdrawal leading to continued consumption.

Research suggests that approximately 8–13% of regular caffeine users may meet proposed diagnostic criteria, with many reporting significant distress, anxiety, insomnia and repeated failed attempts to stop.

Holmes quietly observes:

“Addiction is not measured by legality.”

“It is measured by loss of choice.”

Treatment proves refreshingly simple-but not always easy.

Unlike illicit stimulants, complete abstinence is often unnecessary.

Most patients benefit from gradual reduction.

The authors recommend:

* Educating patients about hidden caffeine sources.

* Recording daily caffeine intake.

* Setting realistic reduction goals.

* Reducing intake by approximately 25% each week.

* Substituting decaffeinated alternatives.

* Using behavioural strategies similar to other substance use disorders.

Abrupt cessation is generally discouraged because withdrawal itself often causes relapse. Randomised studies demonstrate that structured behavioural reduction programmes can substantially reduce caffeine consumption while improving anxiety, sleep and quality of life.

As Holmes leaves the café, he notices something he had overlooked all morning.

Nobody drinks coffee simply because it tastes pleasant.

Some drink it to wake.

Some to work.

Some to think.

Some merely to feel normal.

He realises that caffeine is unique.

Unlike many psychoactive drugs, it quietly weaves itself into ordinary life until its absence becomes louder than its presence.

The mystery, Holmes concludes, is not why caffeine changes the brain.

The mystery is how easily we forget that it does.

Key Takeaways

* Caffeine is the world’s most widely consumed psychoactive substance.

* It acts primarily by antagonising adenosine receptors, indirectly increasing dopaminergic activity.

* Low doses improve alertness and concentration, whereas high doses commonly cause anxiety, jitteriness and insomnia.

* Caffeine intoxication presents with restlessness, tachycardia, gastrointestinal symptoms, tremor and psychomotor agitation.

* Chronic caffeine use produces genuine physical dependence and a well-defined withdrawal syndrome.

* Withdrawal usually begins within 12–24 hours and is characterised by headache, fatigue, low mood and impaired concentration.

* Caffeine may induce clinically significant anxiety and sleep disorders, particularly in susceptible individuals.

* Caffeine Use Disorder is recognised in DSM-5-TR as a condition for further study.

* Behavioural treatment focuses on gradual reduction rather than abrupt cessation.

* Clinicians should routinely assess caffeine intake when evaluating anxiety, insomnia, headaches and unexplained physical symptoms.

Medlock Holmes is summoned to investigate a city that never seems to sleep.

The streets remain alive long after midnight.

Factories work around the clock.

Students study without rest.

Traders chase impossible fortunes.

Artists paint through the night.

Everyone appears driven by an invisible force that promises endless energy, relentless focus, and extraordinary productivity.

Yet Holmes quickly notices another pattern.

The faster the city moves, the more fragile it becomes.

People who once brimmed with confidence now pace the streets in terror.

Windows are barricaded against imagined enemies.

Brilliant careers collapse into paranoia.

Bodies begin to fail long before minds are willing to stop.

Holmes soon realises that he is confronting the world of stimulant-related disorders.

Stimulants-including cocaine, amphetamines, methamphetamine, prescription stimulants such as methylphenidate, and newer synthetic cathinones (”bath salts”)-all share a common feature: they dramatically increase alertness, energy, confidence, and reward by enhancing dopaminergic neurotransmission. Although they differ chemically, they converge upon the brain’s reward circuitry, particularly the dopamine pathways linking the ventral tegmental area to the nucleus accumbens.

Unlike alcohol, whose effects slow the nervous system, stimulants accelerate it.

The heart races.

Blood pressure rises.

Sleep disappears.

Thoughts accelerate.

Confidence grows.

For a time, the world feels conquerable.

But Holmes knows that every borrowed advantage eventually demands repayment.

The chapter explores how stimulant use disorder develops through powerful reinforcement learning. Each episode of stimulant use floods the brain with dopamine, strengthening memories that connect pleasure with the drug, the environment, the people present, and even particular times of day. Gradually, everyday rewards lose their appeal while drug-associated cues become increasingly irresistible. Craving is no longer simply desire-it becomes conditioned biology.

Holmes becomes fascinated by the distinction between positive and negative reinforcement.

Initially, stimulants are taken because they produce euphoria, energy, confidence, and reward.

Later, they are increasingly used simply to escape exhaustion, dysphoria, emotional emptiness, and overwhelming craving.

The pursuit of pleasure quietly transforms into avoidance of suffering.

As Holmes interviews those affected, another pattern emerges.

Not everyone uses stimulants in the same way.

Some binge for days before crashing.

Others remain abstinent for weeks between episodes.

Some use prescription medications appropriately throughout life without developing addiction.

The disorder is defined not by the drug itself, but by the progressive loss of control despite mounting harm. DSM-5 therefore focuses on impaired control, craving, hazardous use, tolerance, withdrawal, and continued use despite significant consequences, with severity ranging from mild to severe depending upon the number of criteria met.

The investigation then turns towards intoxication.

Holmes watches an apparently confident businessman become increasingly suspicious.

Every passing stranger appears threatening.

Ordinary sounds become sinister.

Minor coincidences seem like evidence of elaborate conspiracies.

He learns that stimulant intoxication may progress from heightened confidence to severe paranoia, hallucinations, agitation, seizures, cardiac arrhythmias, hyperthermia, and even sudden death. Methamphetamine-induced psychosis may persist longer than cocaine-induced psychosis and sometimes becomes difficult to distinguish from primary schizophrenia, requiring careful longitudinal assessment.

Eventually every binge ends.

The crash arrives.

Energy vanishes.

Mood collapses.

Sleep returns in overwhelming waves.

Pleasure disappears.

The chapter explains stimulant withdrawal as a state of profound dopamine depletion, characterised by fatigue, dysphoria, hypersomnia, increased appetite, vivid dreams, slowed thinking, and intense craving. Although rarely medically dangerous in itself, withdrawal may be accompanied by severe depression and suicidal thinking, making careful psychiatric assessment essential.

Holmes also uncovers the extensive medical consequences hidden beneath the surface.

Stimulants constrict blood vessels while increasing heart rate and blood pressure.

The result may be myocardial infarction, stroke, cardiomyopathy, aortic dissection, seizures, cognitive impairment, and, particularly with methamphetamine, long-term neurotoxicity and increased risk of Parkinson disease. Repeated intranasal cocaine use damages nasal tissues, while chronic methamphetamine use produces the devastating dental destruction commonly known as “meth mouth.”

The final lesson concerns treatment.

Unlike alcohol or opioid withdrawal, stimulant withdrawal rarely requires complex medical detoxification.

Instead, recovery depends upon rebuilding behaviour.

Holmes finds that the strongest evidence supports psychological interventions rather than medication alone. Contingency management consistently produces the best outcomes by rewarding abstinence and treatment engagement. Cognitive behavioural therapy helps patients recognise triggers, manage cravings, and develop healthier coping strategies, while twelve-step programmes and community support provide long-term reinforcement for recovery. Although numerous medications have been studied, none has yet become an established first-line pharmacological treatment.

As Holmes prepares to leave the sleepless city, dawn finally breaks.

The streets grow quieter.

For the first time, people begin to rest.

He reflects that the greatest illusion stimulants create is not unlimited energy-it is the belief that human beings can permanently outrun the biological limits of the brain.

Eventually, every borrowed hour must be repaid.

Recovery begins not by running faster, but by learning once again how to stop.

Key Takeaways

* Stimulants include cocaine, amphetamines, methamphetamine, prescription stimulants, and synthetic cathinones.

* They primarily act by increasing dopamine transmission within the brain’s reward pathways.

* Stimulant use disorder is characterised by impaired control, craving, and continued use despite harm.

* Intoxication may cause euphoria, insomnia, hypertension, agitation, paranoia, hallucinations, and cardiovascular emergencies.

* Withdrawal typically produces fatigue, depression, hypersomnia, increased appetite, and intense craving.

* Chronic stimulant use alters learning, memory, executive functioning, and reward processing.

* Methamphetamine use is associated with neurotoxicity, cognitive impairment, and increased Parkinson disease risk.

* Stimulant-induced psychosis may resemble primary psychotic disorders and requires careful longitudinal assessment.

* Contingency management has the strongest evidence among psychosocial treatments, supported by CBT and mutual-help programmes.

* No medication has yet become an established first-line treatment for stimulant use disorder.

Medlock Holmes is invited to investigate a city where one establishment appears to be at the centre of almost every celebration.

People gather there after work.

Families celebrate milestones there.

Business deals are made there.

Victories are toasted there.

At first glance, the tavern seems woven naturally into the life of the city.

Yet Holmes begins noticing a different pattern.

The same people keep returning-not because they wish to celebrate, but because they no longer know how to stop.

Relationships begin to fracture.

Careers slowly decline.

Health deteriorates.

Anxiety and depression become more common.

What once appeared to offer freedom gradually becomes a source of dependence.

This chapter explores alcohol-related disorders-the most common substance use disorders encountered in psychiatric practice and among the most misunderstood.

Alcohol is unique because it is both socially accepted and pharmacologically powerful. It acts throughout the brain, altering inhibitory and excitatory neurotransmission, influencing dopamine reward pathways, impairing judgement, memory, sleep, and emotional regulation. With repeated exposure, the brain adapts, leading to tolerance, withdrawal, craving, and eventually dependence in vulnerable individuals.

Holmes soon realises that alcohol problems rarely present in obvious ways. Many people with alcohol use disorder maintain employment, support families, and function successfully for years. The disorder often hides behind symptoms such as anxiety, depression, insomnia, relationship conflict, cognitive impairment, or unexplained medical illness rather than obvious intoxication.

As his investigation deepens, Holmes discovers that alcohol affects virtually every organ system.

The liver struggles to detoxify increasing amounts of ethanol.

The heart weakens.

Peripheral nerves become damaged.

The immune system falts.

Sleep architecture fragments.

Memory begins to fail.

Even brief episodes of intoxication may leave permanent gaps in memory through alcohol-induced blackouts, while prolonged heavy use increases the risk of Wernicke–Korsakoff syndrome and alcohol-related neurocognitive disorders.

The chapter also explores withdrawal-the brain’s response when alcohol suddenly disappears.

What was once chemically suppressed becomes excessively active.

Tremor.

Sweating.

Anxiety.

Insomnia.

Hypertension.

Seizures.

In severe cases, delirium tremens emerges as a medical emergency requiring urgent treatment. Holmes recognises that safe management depends upon careful assessment, timely benzodiazepine therapy, and close monitoring rather than simply asking someone to “stop drinking.”

Another important lesson concerns psychiatric diagnosis.

Heavy alcohol use can produce depression, anxiety, psychosis, sleep disturbance, and cognitive impairment that closely resemble primary psychiatric disorders. Holmes learns that chronology is one of the clinician’s greatest diagnostic tools. Did the psychiatric symptoms precede heavy drinking, or did they emerge during intoxication and withdrawal? Careful timelines often reveal whether symptoms are alcohol-induced or represent independent psychiatric illnesses requiring parallel treatment.

Treatment extends well beyond detoxification.

Holmes discovers that recovery involves rebuilding an entire way of living.

Motivation must be strengthened.

Triggers identified.

Relationships repaired.

Relapse anticipated rather than feared.

Evidence-based psychological therapies, mutual support groups, family involvement, and medications such as acamprosate and naltrexone each contribute to long-term recovery by addressing different parts of the addiction cycle.

As Holmes leaves the city, he looks back at the tavern.

It has not changed.

People still gather there.

Some will drink safely throughout their lives.

Others will unknowingly begin a journey towards dependence.

The difference lies not simply in the substance itself, but in the complex interaction between biology, psychology, environment, and vulnerability.

Alcohol is neither wholly friend nor enemy.

Like many powerful tools, its impact depends upon the relationship people develop with it-and recognising when that relationship has quietly shifted from choice to compulsion.

Key Takeaways

* Alcohol use disorder is one of the most common psychiatric disorders worldwide.

* Alcohol affects multiple neurotransmitter systems, producing intoxication, tolerance, withdrawal, and dependence.

* Many individuals with alcohol use disorder remain employed and outwardly functional.

* Heavy alcohol use can mimic depression, anxiety, psychosis, and cognitive disorders.

* Careful chronology helps distinguish alcohol-induced disorders from independent psychiatric illness.

* Withdrawal ranges from mild tremor to life-threatening delirium tremens.

* Alcohol contributes to significant neurological, hepatic, cardiovascular, gastrointestinal, and cognitive complications.

* Assessment includes history, collateral information, laboratory markers, and screening tools such as the AUDIT.

* Long-term treatment combines psychological therapies, relapse prevention, social support, and selected medications.

* Recovery involves rebuilding a sustainable life rather than simply stopping alcohol consumption.

Imagine Medlock Holmes arriving in a magnificent city renowned for one remarkable feature.

Every citizen possesses complete freedom.

Every street offers choices.

Every marketplace presents opportunities.

Every day, thousands of decisions are made.

Which road to follow.

Which people to trust.

Which risks to take.

Which pleasures to pursue.

At the centre of the city stands the Hall of Choice.

Inside, an intricate council carefully weighs every decision.

Reason speaks.

Memory offers advice.

Emotion contributes experience.

Future consequences are considered.

Rewards are balanced against risks.

Normally, the system works beautifully.

Citizens enjoy pleasure without becoming enslaved by it.

They recover from disappointment.

They learn from mistakes.

They adapt.

Then Holmes notices something unsettling.

Certain visitors begin arriving in the city.

Some carry bottles.

Others offer powders.

Some bring pills.

Others introduce smoke, vapour, crystals, or injections.

At first, these visitors seem harmless.

They promise relief.

Confidence.

Energy.

Sleep.

Escape.

Pleasure.

The citizens welcome them.

Nothing appears unusual.

But gradually, something changes.

The Hall of Choice no longer governs the city.

Its conversations become quieter.

Its influence weakens.

Meanwhile, another building grows larger with every passing day.

The House of Reward.

Here, powerful messengers flood the city with signals of pleasure, relief, and desire.

Each visit strengthens its authority.

Each return becomes easier.

Each absence becomes harder to tolerate.

Soon, the city’s choices no longer feel like choices at all.

Holmes realises he is not investigating a failure of morality.

He is investigating a disease of decision-making.

This chapter introduces substance use disorders as chronic biopsychosocial illnesses that reshape the brain, behaviour, and environment together.

Addiction is not defined simply by the presence of a substance.

It is defined by a pattern.

Repeated use despite accumulating harm.

Powerful cravings.

Difficulty reducing or stopping.

Loss of control.

The consequences spread throughout the city.

Relationships begin to fracture.

Employment suffers.

Physical health deteriorates.

Mental illness becomes more severe.

Communities feel the burden.

Families struggle to understand why promises repeatedly become broken.

Holmes discovers that modern psychiatry no longer views addiction as a failure of willpower.

Instead, it recognises an illness arising from the interaction of biology, psychology, social circumstances, trauma, stress, learning, and environment.

The chapter also introduces the language clinicians use to understand these disorders.

Gone is the older distinction between “abuse” and “dependence.”

Instead, substance use disorders exist along a continuum of severity.

Some individuals experience relatively mild impairment.

Others develop profound disruption affecting nearly every aspect of life.

The degree of illness matters because treatment must be matched to need.

As Holmes continues his investigation, he travels through different districts of the city.

One neighbourhood struggles with alcohol.

Another with opioids.

Others face stimulants, cannabis, tobacco, sedatives, hallucinogens, inhalants, and newer synthetic substances.

Although each district has unique challenges, Holmes notices that they all share remarkably similar patterns.

The substances differ.

The disease does not.

The investigation then widens beyond individual patients.

Holmes steps onto a tower overlooking the entire landscape.

He sees waves of addiction moving through populations.

The opioid crisis.

The rise of fentanyl.

Increasing alcohol-related harm.

The growing use of stimulants.

Changing cannabis laws.

The emergence of vaping.

Each reflects the complex interaction between medicine, public policy, economics, culture, and human behaviour.

Yet Holmes also finds reasons for hope.

Recovery centres stand throughout the city.

Doctors.

Psychologists.

Peer recovery coaches.

Families.

Support groups.

Medications.

Behavioural therapies.

Community programmes.

No single intervention rebuilds the city alone.

Recovery is constructed through many pathways working together.

The greatest lesson of the chapter becomes increasingly clear.

The opposite of addiction is not simply abstinence.

It is the gradual restoration of choice.

As Holmes leaves the Hall of Choice, its lights begin to shine once again.

Not because temptation has disappeared.

But because the city’s ability to choose its future has slowly returned.

Key Takeaways

* Substance use disorders are chronic biopsychosocial diseases rather than moral failings.

* Addiction is characterised by impaired control, craving, continued use despite harm, and physiological adaptation.

* DSM-5-TR conceptualises substance use disorders along a spectrum of severity rather than separate categories of abuse and dependence.

* Biological vulnerability, psychological factors, trauma, social influences, and environmental circumstances all contribute to addiction.

* Different substances affect the brain in different ways but share common underlying mechanisms involving reward and impaired decision-making.

* Substance use disorders commonly coexist with other psychiatric disorders and significantly increase morbidity and mortality.

* Public health crises, including the opioid epidemic and increasing stimulant use, demonstrate the societal impact of addiction.

* Effective treatments include medications, psychological therapies, peer support, and long-term recovery-oriented care.

* Recovery often involves periods of remission and relapse, similar to other chronic medical illnesses.

* Successful treatment focuses not only on reducing substance use but on restoring health, functioning, and the ability to make autonomous choices.

Imagine Medlock Holmes arriving at a grand command centre responsible for coordinating an entire city.

The command centre appears sophisticated and highly organised. It manages communication, planning, navigation, memory, and decision-making for every district.

One day, however, the operators begin making mistakes.

Messages are delayed.

Instructions become confused.

Important information is misplaced.

Decision-making becomes unreliable.

At first, observers assume the command centre itself is failing.

Yet Holmes notices something unusual.

The problems are not originating within the command centre.

Instead, disruptions are arriving from elsewhere.

A contaminated water supply.

A failing power station.

Toxic fumes entering the ventilation system.

Damaged communication cables.

The command centre is responding to problems occurring throughout the wider city.

The command centre represents the brain.

The wider city represents the body.

This chapter explores cognitive disorders that arise not from primary neurodegenerative disease, but from other medical conditions, substances, medications, toxins, or systemic illnesses affecting brain function.

A central lesson emerges immediately: cognition is extraordinarily dependent upon the health of the entire organism.

The brain requires oxygen, nutrients, hormonal regulation, immune stability, metabolic balance, and uninterrupted communication with the rest of the body. When these systems become disrupted, cognitive symptoms may be among the earliest and most prominent signs.

As Holmes investigates, he encounters a remarkable variety of causes.

Endocrine disorders alter cognition through hormonal imbalance.

Liver and kidney disease allow toxic substances to accumulate.

Nutritional deficiencies impair neural function.

Autoimmune diseases generate inflammatory disturbances.

Infections affect the brain directly or indirectly.

Sleep disorders compromise attention and memory.

Cardiovascular disease reduces cerebral blood flow.

Neurological conditions interfere with neural communication.

In every case, the cognitive symptoms are real, but their origin lies beyond the brain itself.

The chapter also explores the cognitive effects of substances.

Holmes enters another district where medications, alcohol, recreational drugs, environmental toxins, and withdrawal states influence the city’s functioning.

Some substances impair attention.

Others affect memory.

Some slow thinking.

Others create confusion, agitation, or altered awareness.

The pattern of impairment often provides clues regarding the underlying cause.

A key theme is reversibility.

Unlike many neurodegenerative disorders, cognitive impairment caused by medical conditions or substances may improve substantially when the underlying problem is identified and treated.

Correcting a vitamin deficiency.

Managing thyroid disease.

Treating infection.

Stopping a problematic medication.

Addressing substance misuse.

Restoring metabolic balance.

The earlier the cause is recognised, the greater the potential for recovery.

Holmes quickly learns that clinicians must resist premature conclusions.

Not every memory complaint represents dementia.

Not every concentration problem reflects psychiatric illness.

Not every episode of confusion indicates primary brain disease.

Sometimes the most important diagnostic question is not “What is happening in the brain?” but rather “What is happening elsewhere that is affecting the brain?”

The chapter highlights the importance of comprehensive assessment, including medical history, physical examination, laboratory testing, medication review, neuroimaging, and collateral information.

The brain cannot be assessed in isolation from the body that supports it.

As Holmes reaches the centre of the command complex, he discovers a vast network connecting every organ system to the city’s central operations.

Signals arrive continuously from the heart, liver, kidneys, endocrine glands, immune system, bloodstream, and environment.

The lesson becomes unmistakable.

The brain does not function alone.

Cognitive disorders due to medical conditions or substances remind us that mental functioning depends upon the health of an entire interconnected system.

For the skilled clinician, recognising those connections may transform a progressive decline into a treatable condition.

Key Takeaways

* Cognitive impairment may arise from medical conditions affecting brain function.

* Endocrine, metabolic, infectious, autoimmune, cardiovascular, nutritional, and neurological disorders can all impair cognition.

* Medications, alcohol, recreational substances, toxins, and withdrawal states may cause significant cognitive symptoms.

* Careful medical assessment is essential when evaluating cognitive complaints.

* Some causes of cognitive impairment are potentially reversible.

* Differential diagnosis is critical to avoid misclassifying treatable conditions as neurodegenerative disease.

* Laboratory testing, medication review, and physical examination are important components of assessment.

* Cognitive symptoms often reflect systemic illness rather than primary brain pathology.

* Early identification and treatment improve outcomes.

* The brain functions within a larger biological system and cannot be understood in isolation.

Imagine Medlock Holmes returning once more to the great library of the mind.

Unlike the previous chapter, the library is still functioning remarkably well.

The catalogue remains largely intact.

Visitors can still find most of the books they need.

The librarians continue their work.

The building remains operational.

Yet Holmes notices subtle signs that something has changed.

A librarian takes longer to locate a familiar volume.

A catalogue entry requires a second search.

A book is occasionally misplaced before being found again.

The library continues to function, but not with the effortless efficiency it once possessed.

This is the world of Mild Cognitive Impairment (MCI).

The chapter explores a state that occupies the space between normal cognitive ageing and major neurocognitive disorder. Individuals experience measurable cognitive decline, yet their overall independence remains largely preserved.

Holmes quickly learns that ageing itself is not a disease.

Many cognitive processes change over time. Names may take longer to retrieve. New information may require more repetition. Processing speed may slow slightly.

These changes are expected.

The challenge lies in determining when such changes exceed what would normally be anticipated.

As Holmes investigates, he discovers that Mild Cognitive Impairment represents an important transitional territory.

Objective evidence of cognitive decline exists, often confirmed through clinical assessment or neuropsychological testing. However, the individual continues to manage daily life with relative independence.

The library is functioning, but its systems are becoming less efficient.

The chapter pays particular attention to amnestic disorders.

Within one wing of the library, Holmes observes a specialised archive responsible for memory formation and retrieval.

The challenge is not simply forgetting where a book was placed.

Rather, the system responsible for recording new information struggles to create reliable entries in the catalogue.

Recent events become difficult to retain.

New learning becomes less efficient.

Questions may be repeated because the memory of asking them was never firmly stored.

Holmes discovers that amnestic disorders can arise from many causes.

Some result from neurological disease.

Others emerge following head injury, nutritional deficiencies, substance use, metabolic disturbances, infections, or damage to structures critical for memory processing.

Not all memory disorders are progressive.

Some remain stable.

Others improve if the underlying cause can be treated.

A central theme of the chapter is uncertainty.

Not everyone with Mild Cognitive Impairment develops dementia.

Some individuals remain stable for years.

Some improve.

Others progress to major neurocognitive disorders.

The clinician’s task is therefore not merely to identify impairment but to understand its pattern, severity, likely cause, and future implications.

As Holmes explores further, he notices something often overlooked.

People with Mild Cognitive Impairment are frequently aware of their difficulties.

Unlike advanced neurocognitive disorders, where insight may diminish, individuals often recognise changes in memory, concentration, or mental efficiency.

This awareness can generate anxiety, frustration, fear, and concern about the future.

The emotional impact of cognitive change becomes part of the story.

The chapter also highlights the importance of early assessment.

Recognising subtle cognitive changes allows clinicians to investigate reversible causes, monitor progression, implement risk reduction strategies, and support individuals and families before substantial functional decline occurs.

Standing within the library’s memory archive, Holmes observes shelves that remain largely intact yet require increasing effort to navigate.

The building still functions.

The knowledge remains present.

The challenge lies in accessing it reliably.

The lesson becomes clear.

Mild Cognitive Impairment and amnestic disorders are not simply disorders of forgetting.

They are disorders of information processing, storage, and retrieval that occupy a crucial boundary between healthy cognitive ageing and more significant cognitive decline.

For clinicians, recognising this boundary may be one of the most important opportunities for early intervention and understanding.

Key Takeaways

* Mild Cognitive Impairment (MCI) involves measurable cognitive decline that exceeds expected ageing.

* Individuals with MCI generally maintain independence in everyday functioning.

* MCI occupies an intermediate position between normal ageing and major neurocognitive disorder.

* Not all individuals with MCI progress to dementia.

* Amnestic disorders primarily affect memory formation, storage, or retrieval.

* Memory impairment may result from neurological, medical, nutritional, traumatic, infectious, or substance-related causes.

* Neuropsychological assessment is often helpful in characterising cognitive deficits.

* Early recognition allows investigation of reversible causes and monitoring over time.

* Insight is often preserved in MCI, contributing to emotional distress and anxiety.

* Assessment should consider cognition, function, emotional wellbeing, and future risk.

Imagine Medlock Holmes returning to the great library introduced in the previous chapter.

At first glance, the library still stands.

Its walls remain intact.

The shelves are still filled with books.

The familiar corridors continue to stretch into the distance.

Yet something profound has changed.

The librarians who once maintained the archives can no longer keep pace with the demands of the system.

Catalogues become incomplete.

Sections lose their organisation.

Books are misplaced and never returned.

Connections between different collections begin to disappear.

The library represents the human brain.

The gradual deterioration of its organisational systems represents a major neurocognitive disorder.

This chapter explores a group of conditions characterised by significant decline in one or more cognitive domains severe enough to interfere with independence and everyday functioning.

Unlike delirium, which develops rapidly and fluctuates, major neurocognitive disorders typically emerge insidiously. Their progression is often measured in months or years rather than hours or days.

Holmes quickly discovers that memory is only one part of the story.

Popular understanding often equates neurocognitive disorders with forgetfulness, but the reality is far more complex.

Different individuals may experience impairments in attention, language, executive functioning, visuospatial abilities, social cognition, learning, reasoning, judgement, or behavioural regulation.

The specific pattern depends on which neural systems are affected.

As Holmes explores the library, he notices that some wings deteriorate more rapidly than others.

One section struggles to create new memories.

Another loses the ability to navigate familiar spaces.

Elsewhere, language archives become difficult to access, while decision-making centres grow increasingly unreliable.

The disorder is not defined by the loss of a single function.

It is defined by a decline significant enough to affect daily life.

The chapter examines how clinicians identify major neurocognitive disorders through careful history-taking, cognitive assessment, functional evaluation, collateral information, neuropsychological testing, and medical investigation.

A central theme is the distinction between cognitive impairment and disability.

Many individuals experience minor cognitive changes without losing independence.

Major neurocognitive disorders are diagnosed when cognitive decline begins to impair essential activities such as managing finances, medications, transportation, communication, work responsibilities, or self-care.

Holmes also discovers that these disorders arise from diverse causes.

Neurodegenerative diseases.

Cerebrovascular disease.

Traumatic brain injury.

Substance-related conditions.

Infections.

Metabolic disorders.

Neurological illnesses.

Although the pathways differ, they converge upon a common destination: progressive disruption of the cognitive systems that support everyday life.

As the investigation continues, Holmes notices another important feature.

The disorder affects not only cognition but identity.

Families often describe subtle personality changes, altered emotional responses, shifts in social behaviour, or changes in decision-making long before severe cognitive deficits become apparent.

The person remains present, yet the ways in which they engage with the world gradually change.

The chapter also highlights the enormous impact on carers and families.

Neurocognitive disorders rarely affect individuals alone.

They alter relationships, roles, responsibilities, and future plans.

The challenge therefore extends beyond diagnosis to include support, adaptation, planning, and compassionate care.

Standing within the library’s central archive, Holmes observes some shelves dimming while others continue to glow brightly.

Even amidst decline, many strengths remain.

Procedural skills, emotional connections, creativity, humour, and personal values may persist long after other cognitive abilities have changed.

The lesson becomes clear.

Major neurocognitive disorders are not simply disorders of memory.

They are disorders of complex brain systems that support independent living, relationships, and personal identity.

The clinician’s task is not merely to identify decline, but to understand its pattern, determine its cause, and help individuals and families navigate the journey that follows.

Key Takeaways

* Major neurocognitive disorders involve significant decline in one or more cognitive domains.

* Cognitive decline interferes with independence and daily functioning.

* Memory impairment is common but not universally present.

* Multiple domains may be affected, including attention, language, executive function, visuospatial abilities, and social cognition.

* Major neurocognitive disorders usually develop gradually over time.

* Diagnosis requires assessment of both cognition and functional abilities.

* Numerous medical and neurological conditions can cause major neurocognitive disorders.

* Collateral history from family members is often essential.

* The disorders affect identity, relationships, and quality of life as well as cognition.

* Management focuses on diagnosis, support, adaptation, safety, and maintaining quality of life.